Treasury promises £434m to support medicines supply chain after no-deal Brexit
The UK chancellor has committed to spending an extra £434m on ensuring the continued supply of medicines in the event of a no-deal Brexit.
The money forms part of a larger announcement of funding worth £2.1bn for no-deal Brexit preparations across several government departments.
In the Treasury statement , Sajid Javid — who was appointed as UK chancellor on 24 July 2019 by the new prime minister Boris Johnson — said the £434m will be “made available to help ensure continuity of vital medicines and medical products, including through freight capacity, warehousing and stockpiling”.
The Department of Health and Social Care (DHSC) was previously allotted £50m for no-deal Brexit preparations in 2019/2020, having set aside £3m to transport short-life medicines and medical devices and spent an undisclosed amount of money in the “low tens of millions” of pounds on refrigerated storage.
However, the Treasury has confirmed to Electronicjuice that the latest tranche of funding will be entirely new money.
Plans to maintain the drugs supply in the event of a no-deal Brexit were put on hold after two Brexit extensions were agreed between the UK government and the EU, with the UK now expected to leave the EU on 31 October 2019.
Following the second extension in April 2019, the DHSC wrote to pharmaceutical firms asking them to keep their previously-agreed six-week rolling stockpile of drugs “in place but on hold” until further notice.
Then in June 2019, , wrote to drugs firms and the wider healthcare sector setting out further no-deal Brexit planning and warning that there would be “significant disruption” for six months in the event of the UK leaving the UK with no agreement in place.
Citation: Electronicjuice DOI: 10.1211/PJ.2019.20206888
Recommended from Pharmaceutical Press
Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.£138.50
Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.£262.50
Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.£40.00
A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.£33.00
This unique textbook covers the role of basic pharmaceutics in clinical outcomes and in explaining the behaviour of medicines in the body.£27.00